Vistagen Therapeutics (NASDAQ:VTGN) Stock Crosses Below 50-Day Moving Average – Here’s What Happened

Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $2.88 and traded as low as $2.62. Vistagen Therapeutics shares last traded at $2.65, with a volume of 121,644 shares trading hands.

Vistagen Therapeutics Stock Performance

The firm has a market capitalization of $76.48 million, a PE ratio of -1.79 and a beta of 0.62. The business’s 50 day moving average is $2.88 and its two-hundred day moving average is $2.91.

Vistagen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings results on Thursday, February 13th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.02. The firm had revenue of $230 billion during the quarter, compared to analyst estimates of $0.18 million. Vistagen Therapeutics had a negative return on equity of 48.12% and a negative net margin of 6,777.08%. As a group, equities research analysts predict that Vistagen Therapeutics, Inc. will post -1.77 EPS for the current year.

Institutional Investors Weigh In On Vistagen Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Valence8 US LP purchased a new position in Vistagen Therapeutics during the third quarter valued at approximately $103,000. HighTower Advisors LLC bought a new position in Vistagen Therapeutics in the 3rd quarter valued at $64,000. Jane Street Group LLC purchased a new position in shares of Vistagen Therapeutics during the 3rd quarter valued at $59,000. Virtu Financial LLC grew its position in shares of Vistagen Therapeutics by 30.5% during the 3rd quarter. Virtu Financial LLC now owns 20,210 shares of the company’s stock valued at $61,000 after purchasing an additional 4,722 shares in the last quarter. Finally, R Squared Ltd bought a new position in shares of Vistagen Therapeutics in the fourth quarter worth $25,000. 78.39% of the stock is currently owned by institutional investors.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.